Chinwe C Madubata1, Ying Liu2,3, Melody S Goodman1,4, Shumei Yun5, Jennifer Yu1, Min Lian4,6, Graham A Colditz1,4. 1. Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8100, St. Louis, MO, 63110, USA. 2. Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8100, St. Louis, MO, 63110, USA. liuyi@wudosis.wustl.edu. 3. Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO, USA. liuyi@wudosis.wustl.edu. 4. Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO, USA. 5. Missouri Department of Health and Senior Services, Jefferson City, MO, USA. 6. Division of General Medical Sciences, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Abstract
PURPOSE: To investigate whether treatment (surgery, radiation therapy, and endocrine therapy) contributes to racial disparities in outcomes of ductal carcinoma in situ (DCIS). PATIENTS AND METHODS: The analysis included 8184 non-Hispanic White and 954 non-Hispanic Black women diagnosed with DCIS between 1996 and 2011 and identified in the Missouri Cancer Registry. Logistic regression models were used to estimate odds ratios (ORs) of treatment for race. We used Cox proportional hazards regression models to estimate hazard ratios (HRs) of ipsilateral breast tumor (IBT) and contralateral breast tumor (CBT) for race. RESULTS: There was no significant difference between Black and White women in utilization of mastectomy (OR 1.16; 95 % CI 0.99-1.35) or endocrine therapy (OR 1.19; 95 % CI 0.94-1.51). Despite no significant difference in underutilization of radiation therapy (OR 1.14; 95 % CI 0.92-1.42), Black women had higher odds of radiation delay, defined as at least 8 weeks between surgery and radiation (OR 1.92; 95 % CI 1.55-2.37). Among 9138 patients, 184 had IBTs and 326 had CBTs. Black women had a higher risk of IBTs (HR 1.69; 95 % CI 1.15-2.50) and a comparable risk of CBTs (HR 1.19; 95 % CI 0.84-1.68), which were independent of pathological features and treatment. CONCLUSION: Racial differences in DCIS treatment and outcomes exist in Missouri. This study could not completely explain the higher risk of IBTs in Black women. Future studies should identify differences in timely initiation and completion of treatment, which may contribute to the racial difference in IBTs after DCIS.
PURPOSE: To investigate whether treatment (surgery, radiation therapy, and endocrine therapy) contributes to racial disparities in outcomes of ductal carcinoma in situ (DCIS). PATIENTS AND METHODS: The analysis included 8184 non-Hispanic White and 954 non-Hispanic Black women diagnosed with DCIS between 1996 and 2011 and identified in the Missouri Cancer Registry. Logistic regression models were used to estimate odds ratios (ORs) of treatment for race. We used Cox proportional hazards regression models to estimate hazard ratios (HRs) of ipsilateral breast tumor (IBT) and contralateral breast tumor (CBT) for race. RESULTS: There was no significant difference between Black and White women in utilization of mastectomy (OR 1.16; 95 % CI 0.99-1.35) or endocrine therapy (OR 1.19; 95 % CI 0.94-1.51). Despite no significant difference in underutilization of radiation therapy (OR 1.14; 95 % CI 0.92-1.42), Black women had higher odds of radiation delay, defined as at least 8 weeks between surgery and radiation (OR 1.92; 95 % CI 1.55-2.37). Among 9138 patients, 184 had IBTs and 326 had CBTs. Black women had a higher risk of IBTs (HR 1.69; 95 % CI 1.15-2.50) and a comparable risk of CBTs (HR 1.19; 95 % CI 0.84-1.68), which were independent of pathological features and treatment. CONCLUSION: Racial differences in DCIS treatment and outcomes exist in Missouri. This study could not completely explain the higher risk of IBTs in Black women. Future studies should identify differences in timely initiation and completion of treatment, which may contribute to the racial difference in IBTs after DCIS.
Entities:
Keywords:
Breast cancer; Cancer disparity; Ductal carcinoma in situ; Race; Second breast tumors
Authors: Laura C Collins; Ninah Achacoso; Reina Haque; Larissa Nekhlyudov; Suzanne W Fletcher; Charles P Quesenberry; Stuart J Schnitt; Laurel A Habel Journal: Breast Cancer Res Treat Date: 2013-04-27 Impact factor: 4.872
Authors: Benjamin D Smith; Bruce G Haffty; Thomas A Buchholz; Grace L Smith; Deron H Galusha; Justin E Bekelman; Cary P Gross Journal: J Natl Cancer Inst Date: 2006-09-20 Impact factor: 13.506
Authors: Azadeh Stark; Robert Stapp; Aditya Raghunathan; Xiaowei Yan; H Lester Kirchner; Jennifer Griggs; Lisa Newman; Dhananjay Chitale; Andrew Dick Journal: Breast Cancer Res Treat Date: 2011-08-27 Impact factor: 4.872
Authors: Lawrence J Solin; Alain Fourquet; Frank A Vicini; Marie Taylor; Ivo A Olivotto; Bruce Haffty; Eric A Strom; Lori J Pierce; Lawrence B Marks; Harry Bartelink; Marsha D McNeese; Anuja Jhingran; Elaine Wai; Nina Bijker; Francois Campana; Wei-Ting Hwang Journal: Cancer Date: 2005-03-15 Impact factor: 6.860
Authors: Tomasz P Srokowski; Shenying Fang; Zhigang Duan; Thomas A Buchholz; Gabriel N Hortobagyi; James S Goodwin; Sharon H Giordano Journal: Cancer Date: 2008-07-01 Impact factor: 6.860